ライフサイエンスコーパス: central sleep apnea

1 reduced ejection fraction and predominantly central sleep apnea.

2 nts with heart failure to the development of central sleep apnea.

3 esponse to carbon dioxide than those without central sleep apnea (5.1+/-3.1 vs. 2.1+/-1.0 liters per

4 and 20 +/- 27; P = 0.015), the prevalence of central sleep apnea (78% and 39%; P = 0.01), and the mea

5 dose of acetazolamide before sleep improves central sleep apnea and related daytime symptoms.

6 btypes including obstructive sleep apnea and central sleep apnea and with event severity, hypoxemia,

7 Ten had central sleep apnea, and 10 did not.

8 Forty percent of all patients had central sleep apnea, and 11% had obstructive sleep apnea

9 ng air leaks, patient-ventilator asynchrony, central sleep apnea, and glottic closure.

10 nea appears to have an adverse effect on SV, central sleep apnea appears to have little or slightly p

11 cs have a high prevalence of obstructive and central sleep apnea associated with Cheyne-Stokes respir

12 Central sleep apnea associated with Cheyne-Stokes respir

13 for considering obstructive sleep apnea and central sleep apnea associated with Cheyne-Stokes respir

14 reduced ejection fraction and predominantly central sleep apnea, but all-cause and cardiovascular mo

15 that uses a noninvasive ventilator to treat central sleep apnea by delivering servo-controlled inspi

16 We encountered a young woman with severe central sleep apnea caused by a medullary glioma located

17 aseline sleep indices: apnea-hypopnea index, central sleep apnea (central apnea index, >/=5 vs. <5),

18 rpose of this study was to determine whether central sleep apnea (CSA) contributes to mortality in pa

19 To understand the pathogenesis of central sleep apnea (CSA) in patients with congestive he

20 Central sleep apnea (CSA) is a highly prevalent, though

21 Background: Central sleep apnea (CSA) is common among patients with

22 Central sleep apnea (CSA) is not usually associated with

23 including obstructive sleep apnea (OSA) and central sleep apnea (CSA), significantly impairs sleep q

24 failure (HF) and either obstructive (OSA) or central sleep apnea (CSA).

25 Central sleep apnea frequently occurs in patients with h

26 Patients who met the criteria for central sleep apnea had significantly more episodes of c

27 Patients with central sleep apnea have a diminished cerebrovascular re

28 on abnormality to the presence or absence of central sleep apnea in patients with heart failure.

29 on dioxide contributes to the development of central sleep apnea in some patients with heart failure.

30 the SERVE-HF (Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure) trial res

31 Central sleep apnea, in its various forms, is generally

32 sed whether elevations in the obstructive or central sleep apnea index or the presence of Cheyne-Stok

33 ates additional sleep disturbances-including central sleep apnea, insomnia, and restless legs syndrom

34 positive predictive value of a low PaCO2 for central sleep apnea is 78%.

35 Central sleep apnea is associated with poor prognosis an

36 ing whether an individual has obstructive or central sleep apnea is fundamental to selecting the appr

37 of central apnea per hour than those without central sleep apnea (mean [+/-SD], 35+/-24 vs. 0.5+/-1.0

38 Central sleep apnea (odds ratio [OR], 2.58; 95% confiden

39 ep apnea (central apnea index, >/=5 vs. <5), central sleep apnea or Cheyne-Stokes respiration, obstru

40 .18-5.66) and Cheyne-Stokes respiration with central sleep apnea (OR, 2.27; 95% CI, 1.13-4.56), but n

41 ized by fluid overload, both obstructive and central sleep apnea (OSA and CSA) are common.

42 art failure with (n = 9) and without (n = 8) central sleep apnea using transcranial ultrasound during

43 is association persisted after subjects with central sleep apnea were excluded.